| 195.34 -1.11 (-0.57%) | 06-05 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 231.21 |
1-year : | 240.57 |
| Resists | First : | 197.95 |
Second : | 205.97 |
| Pivot price | 193.17  |
|||
| Supports | First : | 185 |
Second : | 153.91 |
| MAs | MA(5) : | 193.76 |
MA(20) : | 194.21 |
| MA(100) : | 185.96 |
MA(250) : | 163.67 |
|
| MACD | MACD : | 1.7 |
Signal : | 1.8 |
| %K %D | K(14,3) : | 58.7 |
D(3) : | 45.1 |
| RSI | RSI(14): 54.2 |
|||
| 52-week | High : | 205.97 | Low : | 121.05 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ BIIB ] has closed below upper band by 31.5%. Bollinger Bands are 42% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 200.72 - 201.88 | 201.88 - 202.92 |
| Low: | 192.54 - 193.79 | 193.79 - 194.91 |
| Close: | 193.56 - 195.54 | 195.54 - 197.34 |
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Fri, 05 Jun 2026
Biogen’s Salanersen Win Adds New Dimension To SMA Growth Story - simplywall.st
Fri, 05 Jun 2026
FMR LLC holds 16.65M Biogen shares (BIIB) — 11.3% reported - Stock Titan
Fri, 05 Jun 2026
Lost Money on Biogen Inc. (BIIB)? Contact The Gross Law Firm Regarding an Ongoing Investigation - GlobeNewswire
Thu, 04 Jun 2026
BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm - Barchart.com
Thu, 04 Jun 2026
BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm - Business Wire
Thu, 04 Jun 2026
Biogen (BIIB) Presents Promising Data for Dapirolizumab Pegol at EULAR 2026 - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 148 (M) |
| Shares Float | 147 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 96.4 (%) |
| Shares Short | 4,730 (K) |
| Shares Short P.Month | 4,410 (K) |
| EPS | 9.28 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 126.37 |
| Profit Margin | 13.8 % |
| Operating Margin | 22.8 % |
| Return on Assets (ttm) | 5.9 % |
| Return on Equity (ttm) | 7.6 % |
| Qtrly Rev. Growth | 1.8 % |
| Gross Profit (p.s.) | 52.96 |
| Sales Per Share | 67.32 |
| EBITDA (p.s.) | 23.97 |
| Qtrly Earnings Growth | 31.1 % |
| Operating Cash Flow | 2,590 (M) |
| Levered Free Cash Flow | 1,930 (M) |
| PE Ratio | 21.02 |
| PEG Ratio | 3.9 |
| Price to Book value | 1.54 |
| Price to Sales | 2.9 |
| Price to Cash Flow | 11.13 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|